60 Degrees Pharmaceuticals (SXTP) Expected to Announce Quarterly Earnings on Thursday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($2.28) per share and revenue of $0.5350 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

60 Degrees Pharmaceuticals Trading Down 6.2%

Shares of 60 Degrees Pharmaceuticals stock opened at $1.83 on Tuesday. 60 Degrees Pharmaceuticals has a 12-month low of $1.36 and a 12-month high of $17.68. The company has a market cap of $1.94 million, a price-to-earnings ratio of -0.13 and a beta of 3.01. The company’s 50-day moving average price is $3.11 and its 200-day moving average price is $4.07.

Wall Street Analyst Weigh In

SXTP has been the topic of a number of analyst reports. Ascendiant Capital Markets decreased their target price on shares of 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating on the stock in a report on Friday, November 28th. Wall Street Zen raised shares of 60 Degrees Pharmaceuticals to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright upped their price target on shares of 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $17.60.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.